Methods: Archived H. pylori isolates previously submitted to the clinical microbiology laboratory at Mayo Clinic for antimicrobial susceptibility testing (AST) were retrieved. AST had been performed by agar dilution according to CLSI guidelines. The isolates were thawed, cultured on Columbia agar under microaerophilic conditions at 35°C, and then lysed using bead beating. A 150 bp segment of the 23S rRNA gene was amplified via polymerase chain reaction and subsequently bidirectionally sequenced using dye-terminator technology. The presence of mutations at the 2143 and/or 2142 positions was recorded and compared to prior AST results.
Results: A total of 118 H. pylori isolates were tested. 7 isolates yielded insufficient H. pylori DNA for sequencing or did not have prior clarithromycin AST performed and were excluded from further analysis. For the remaining 111 isolates, there was concordance between phenotypic AST and genotypic results in 106 (95%) isolates. Of these, 21 (20%) were susceptible to clarithromycin and 85 (80%) were resistant. An A2143G mutation was identified in 70 (82%) isolates, A2142G in 12 (14%), and A2142C in 3 (4%). There was discordance between AST and genotype in 5 (5%) isolates; 3 had a resistant phenotype but a wild-type sequence, and 2 had a susceptible phenotype but an A2143G mutation.
Conclusion: 23S rRNA gene mutations predict phenotypic resistance to clarithromycin in clinical H. pylori isolates. Resistance was most commonly conferred by A2143G, followed by A2142G and A2142C point mutations. The prevalence of each mutation in the United States is similar to that reported from other parts of the world.
N. Cole, None
P. Kohner, None
R. Patel, Roche: Consultant , Travel reimbursement
TIB: Patent Holder , Licensing agreement or royalty
IDSA: Editor , Travel reimbursement and editor's stipend